SBIR Phase I: Biotransformable Block Terpolymers for Drug-Eluting Stents

SBIR 第一阶段：用于药物洗脱支架的生物可转化嵌段三元共聚物

• 批准号: 0712489
• 负责人: Lisa Kemp
• 金额: --
• 依托单位: Ablitech, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0712489&HistoricalAwards=false
• 关键词: SBIR; Phase; Biotransformable; Block; Terpolymers

This Small Business Innovation Research (SBIR) Phase I research research project aims to develop a polymer system for drug eluting coronary stents (DES). The material is expected to provide higher drug loading with a controlled drug release profile, as well as tunable mechanical properties over the lifetime of the stent. This will be accomplished using block terpolymers of specific composition to which drug molecules will be covalently attached. Recent advances in DES technology have increased the success rate of CHD treatment; however, restenosis (re-blockage of the artery through the stent) occurs in 10% of the implanted stents. Also currently available drug eluting coatings deliver the bulk of the loaded drug within the first 48 hours of stent placement, with little to no delivery after 30 days. Thus a new type of stent that can overcome the limitations of current stents would be of significant value.

这项小型企业创新研究（SBIR）I期研究项目旨在开发用于冠状动脉支架（DES）的聚合物系统。预计该材料将在支架的寿命内提供更高的药物释放谱以及可调的机械性能。这将使用具有特定组成的块状聚合物来实现，并将药物分子共同附着在其中。 DE技术的最新进展提高了CHD治疗的成功率。然而，重新狭窄（通过支架重新堵塞动脉）发生在10％的植入支架中。目前，目前可用的药物洗脱涂料在支架放置的前48小时内提供了大部分装载药物，而30天后几乎没有交付。因此，可以克服当前支架局限性的新型支架将具有重要的价值。